J-Y Pierga1, F-C Bidard1, A Autret2, T Petit3, F Andre4, F Dalenc5, C Levy6, J-M Ferrero7, G Romieu8, J Bonneterre9, F Lerebours10, T Bachelot11, P Kerbrat12, M Campone13, J-C Eymard14, M-A Mouret-Reynier15, J Gligorov16, A-C Hardy-Bessard17, A Lortholary18, P Soulie13, J-M Boher2, C Proudhon1, E Charafe-Jaufret19,20, J Lemonnier21, F Bertucci20,22, P Viens20,22. 1. Medical Oncology Department, Institut Curie, PSL Research University, Paris, France. 2. Biostatistics Department, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille. 3. Medical Oncology Department, Centre Paul Strauss, Strasbourg. 4. Medical Oncology Department, Gustave Roussy INSERM Unit U981, Université Paris Sud, Villejuif. 5. Medical Oncology Department, Institut Claudius Regaud, IUCT, Toulouse. 6. Medical Oncology Department, Centre François Baclesse, Caen. 7. Medical Oncology Department, Centre Antoine Lacassagne, Nice. 8. Medical Oncology Department, Institut du Cancer de Montpellier, Montpellier. 9. Medical Oncology Department, Centre Oscar Lambret, Lille. 10. Medical Oncology Department, Institut Curie, Saint Cloud. 11. Medical Oncology Department, Centre Léon Bérard, Lyon. 12. Medical Oncology Department, Centre Eugène Marquis, Rennes. 13. Medical Oncology Department, Institut de Cancérologie de l'Ouest, ICO Angers Nantes. 14. Medical Oncology Department, Institut Jean Godinot, Reims. 15. Medical Oncology Department, Centre Jean Perrin, Clermont Ferrand. 16. Medical Oncology Department, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, Université Pierre et Marie Curie, Paris. 17. Centre Armoricain de Radiothérapie d'Imagerie médicale et d'Oncologie, Plérin. 18. Centre Catherine de Sienne, Nantes. 19. Pathology Department, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille. 20. Aix-Marseille Université, Marseille. 21. R&D UNICANCER, UCBG, Paris. 22. Department of Medical Oncology, Centre de Recherche en Cancé rologie de Marseille, Institut Paoli-Calmettes, Marseille, France.
Abstract
Background: We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective trials of patients with inflammatory breast cancer (IBC) treated with neoadjuvant chemotherapy combined with neoadjuvant and adjuvant bevacizumab. Patients and methods: Nonmetastatic T4d patients were enrolled in two phase II multicentre trials, evaluating bevacizumab in combination with sequential neoadjuvant chemotherapy of four cycles of FEC followed by four cycles of docetaxel in HER2-negative tumour (BEVERLY-1) or docetaxel and trastuzumab in HER2-positive tumour (BEVERLY-2). CTC and CEC were detected in 7.5 and 4 ml of blood, respectively, with the CellSearch System. Results: From October 2008 to September 2010, 152 patients were included and 137 were evaluable for CTC and CEC. At baseline, 55 patients had detectable CTC (39%). After four cycles of chemotherapy, a dramatic drop in CTC to a rate of 9% was observed (P < 0.01). Pathological complete response (pCR) rate was 40%. No correlation was found between CTC or CEC levels and pCR rate. Median follow-up was 43 months. CTC detection (≥1 CTC/7.5 ml) at baseline was associated with shorter 3-year disease-free survival (39% versus 70% for patients without CTC, P < 0.01, HR 2.80) and shorter 3-year overall survival (OS) (P < 0.01). In multivariate analysis, independent prognostic parameters for shorter survival were absence of hormonal receptors, no pCR and CTC detection at baseline. CEC level at baseline or variations during treatment had no prognostic value. Conclusion: In this pooled analysis of two prospective trials in nonmetastatic IBC, detection rate of CTC was 39% with a strong and independent prognostic value for survival. Combination of pCR after neoadjuvant treatment with no CTC detection at baseline isolated a subgroup of IBC with excellent OS (94% 3-year OS), suggesting that CTC count could be part of IBC stratification in prospective trials.
Background: We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective trials of patients with inflammatory breast cancer (IBC) treated with neoadjuvant chemotherapy combined with neoadjuvant and adjuvant bevacizumab. Patients and methods: Nonmetastatic T4d patients were enrolled in two phase II multicentre trials, evaluating bevacizumab in combination with sequential neoadjuvant chemotherapy of four cycles of FEC followed by four cycles of docetaxel in HER2-negative tumour (BEVERLY-1) or docetaxel and trastuzumab in HER2-positive tumour (BEVERLY-2). CTC and CEC were detected in 7.5 and 4 ml of blood, respectively, with the CellSearch System. Results: From October 2008 to September 2010, 152 patients were included and 137 were evaluable for CTC and CEC. At baseline, 55 patients had detectable CTC (39%). After four cycles of chemotherapy, a dramatic drop in CTC to a rate of 9% was observed (P < 0.01). Pathological complete response (pCR) rate was 40%. No correlation was found between CTC or CEC levels and pCR rate. Median follow-up was 43 months. CTC detection (≥1 CTC/7.5 ml) at baseline was associated with shorter 3-year disease-free survival (39% versus 70% for patients without CTC, P < 0.01, HR 2.80) and shorter 3-year overall survival (OS) (P < 0.01). In multivariate analysis, independent prognostic parameters for shorter survival were absence of hormonal receptors, no pCR and CTC detection at baseline. CEC level at baseline or variations during treatment had no prognostic value. Conclusion: In this pooled analysis of two prospective trials in nonmetastatic IBC, detection rate of CTC was 39% with a strong and independent prognostic value for survival. Combination of pCR after neoadjuvant treatment with no CTC detection at baseline isolated a subgroup of IBC with excellent OS (94% 3-year OS), suggesting that CTC count could be part of IBC stratification in prospective trials.
Authors: Mark Jesus M Magbanua; Oleksandr Savenkov; Erik J Asmus; Karla V Ballman; Janet H Scott; John W Park; Maura Dickler; Ann Partridge; Lisa A Carey; Eric P Winer; Hope S Rugo Journal: Clin Cancer Res Date: 2020-06-25 Impact factor: 12.531
Authors: Yoon-Sim Yap; Man Chun Leong; Yong Wei Chua; Kiley Wei Jen Loh; Guek Eng Lee; Elaine Hsuen Lim; Rebecca Dent; Raymond Chee Hui Ng; John Heng-Chi Lim; Garima Singh; Angela Tan; Guofeng Guan; Andrew Wu; Yi Fang Lee; Ali Asgar S Bhagat; Darren Wan-Teck Lim Journal: PLoS One Date: 2019-09-25 Impact factor: 3.240
Authors: Anna Jakabova; Zuzana Bielcikova; Eliska Pospisilova; Lubos Petruzelka; Piotr Blasiak; Vladimir Bobek; Katarina Kolostova Journal: Ther Adv Med Oncol Date: 2021-07-13 Impact factor: 8.168